← Back to Search

Non-invasive Brain Stimulation

TMS for Cerebellar Ataxia

N/A
Waitlist Available
Led By Amanda S Therrien, PhD
Research Sponsored by Albert Einstein Healthcare Network
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet safety criteria for receipt of transcranial magnetic stimulation
Normal or corrected-to-normal vision
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

Study Summary

This trial will study if people with cerebellar degeneration can learn better with brain stimulation.

Who is the study for?
This trial is for individuals with cerebellar ataxia due to cerebellar degeneration. Participants must have normal or corrected vision and hearing, and meet safety criteria for transcranial magnetic stimulation (TMS). They cannot join if they have drug abuse history, sensory loss in arms, cognitive issues affecting testing or consent, or arm injuries causing pain.Check my eligibility
What is being tested?
The study aims to see if the activity level in the primary motor cortex can predict how well people with cerebellar damage learn motor skills. It also tests whether using TMS to change motor cortex activity improves their ability to learn new movements.See study design
What are the potential side effects?
TMS may cause discomfort at the stimulation site, headache, lightheadedness, or seizures in very rare cases. Most side effects are mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am cleared to receive brain stimulation treatment.
Select...
My vision is normal or corrected to normal with glasses or contacts.
Select...
My hearing is normal or corrected to normal.
Select...
I have been diagnosed with cerebellar ataxia due to cerebellar degeneration.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cortical Silent Period
International Cooperative Ataxia Rating Scale Limb Coordination Sub-Score
International Cooperative Ataxia Rating Scale Total Score
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: rTMS InterventionExperimental Treatment1 Intervention
In aim 2 of the study, participants receive a repetitive transcranial magnetic stimulation intervention called theta burst stimulation (TBS) to study its effect on motor learning behavior. All participants will complete 3 sessions in which they will receive continuous TBS, intermittent TBS, or sham TBS before completing a behavioral motor learning task. The order of TBS sessions will be counter-balanced across participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation (TMS)
2018
Completed Phase 4
~570

Find a Location

Who is running the clinical trial?

Albert Einstein Healthcare NetworkLead Sponsor
64 Previous Clinical Trials
868,700 Total Patients Enrolled
Medical University of South CarolinaOTHER
932 Previous Clinical Trials
7,394,378 Total Patients Enrolled
Amanda S Therrien, PhDPrincipal InvestigatorMoss Rehabilitation Research Institute

Media Library

TMS (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05351255 — N/A
Cerebellar Ataxia Research Study Groups: rTMS Intervention
Cerebellar Ataxia Clinical Trial 2023: TMS Highlights & Side Effects. Trial Name: NCT05351255 — N/A
TMS (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05351255 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies for potential participants in this clinical trial?

"Indeed, according to clinicaltrials.gov the trial is recruiting participants as of this moment in time. The initial post was published on July 1st 2022 and recently updated on July 18th 2022. Only 12 patients are needed across one medical centre for enrollment into the study."

Answered by AI

Are there any restrictions as to who can participate in this experiment based on age?

"This trial is accepting applicants who are aged 18 or above and below the age of 80."

Answered by AI

What is the target recruitment for this investigation?

"Affirmative. The details of this study, which was initially posted on July 1st 2022 and updated most recently on the 18th of July, are currently available to view on clinicaltrials.gov. 12 individuals need to be admitted from a single site in order for the trial to reach completion."

Answered by AI

Does this clinical trial have eligibility criteria that potential participants must meet?

"For this clinical trial, 12 people with hypermetria who are aged between 18 and 80 will be admitted. To qualify for the study, applicants must have a diagnosis of cerebellar ataxia from cerebellar degeneration as well as regular vision and hearing capabilities; moreover, they need to fulfil safety standards required for transcranial magnetic stimulation treatments."

Answered by AI

Who else is applying?

What state do they live in?
New York
What site did they apply to?
Moss Rehabilitation Research Institute
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex
Amanda Therrien, PhD 2022. "Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05351255.
All > Cerebellar Ataxia
~2 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top